Overcoming Deadly Diseases
Phase 3 ACTION Study of ONC201 (dordaviprone) Now Enrolling
Improving and Extending Lives
Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.
Chimerix Announces the initiation of the ACTION study for patients with the H3K27M mutation.
On the road with Chimerix: SNO Annual Meeting 2023
Come visit us at the 28th Meeting of the Society for Neuro-Oncology (SNO) in Vancouver, Canada, November 16-19, 2023. Our team will be onsite to discuss ONC201, the Phase 3 ACTION study, and how using molecular profiling to identify patients most likely to benefit from therapy is driving advances in the treatment of glioma.
On Saturday, November 18th at 12:45 PM, please join us in room 205-207 for our sponsored satellite symposium will discuss the current diagnosis, treatment strategies, and clinical trials for H3 K27M-mutant diffuse glioma.
The H3 K27M mutation frequently occurs in diffuse midline glioma (DMG) and confers an inferior prognosis with an overall survival of only one year. While most commonly found in DMG, the H3 K27M mutation is occasionally identified in hemispheric glioma as well. Radiation is thought to confer only transient benefit and there are currently no approved systemic therapies specifically for this disease. H3 K27M-mutant glioma is associated with unmethylated MGMT-promoter status, which has been associated with high grade glioma resistance to temozolomide. Together, these factors underscore the urgency of unmet need for novel, effective therapeutics for H3 K27M-mutant diffuse glioma.
- Chimerix Promotes Michelle LaSpaluto to Chief Financial Officeron December 4, 2023
- Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)on November 24, 2023